News & Updates

Maintenance therapy with niraparib significantly extends progression-free survival (PFS) compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to treatment with first-line platinum-based chemotherapy, according to the PRIME* trial.

In patients with locally advanced pancreatic cancer, treatment with intra-arterial gemcitabine leads to better survival and safety outcomes compared with standard-of-care therapy with intravenous gemcitabine/nab-paclitaxel, according to the first interim analysis of the phase III TIGeR-PaC trial presented at ESMO GI 2023.

Several cancer patients have benefitted from nonstandard of care (non-SOC) recommendations by the regional precision medicine molecular tumour board (PMMTB), reports a study. Also, additional processes have been implemented to improve the accessibility of non-SOC treatment.

Topical diclofenac gel significantly reduced the incidence of hand-foot syndrome (HFS) in patients with gastrointestinal (GI) cancer receiving capecitabine, according to findings from the exploratory subgroup analysis of the D-ToRCH* trial.

In the treatment of patients with esophageal cancer, proton-based radiotherapy appears to yield better safety and efficacy outcomes including organs at risk (OARs) doses, toxicity, and prognosis when compared with photon therapy, according to a meta-analysis.